Adult‐onset Still's disease after SARS‐Cov‐2 infection
暂无分享,去创建一个
F. Said | M. Lamloum | M. Houman | T. B. Achour | I. Naceur | I. Ghorbel | Wiem Ben Elhaj | Maysam Jridi | M. Smiti
[1] H. Maecker. Immune profiling of COVID-19: preliminary findings and implications for the pandemic , 2021, Journal for ImmunoTherapy of Cancer.
[2] M. Hallek,et al. First manifestation of adult-onset Still's disease after COVID-19 , 2021, The Lancet Rheumatology.
[3] F. Montorsi,et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study , 2021, The Lancet Rheumatology.
[4] Mohammed Samannodi,et al. Diagnosis of Adult Onset Still’s Disease in a Patient Who has recovered from Coronavirus-19 , 2021, Clinical medicine insights. Case reports.
[5] J. D. de Carvalho. COVID-19 in Still's disease. , 2020, European review for medical and pharmacological sciences.
[6] Hongyang Wang,et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing , 2020, Cell Discovery.
[7] Hongyang Wang,et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing , 2020, Cell Discovery.
[8] Z. Memish,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.
[9] N. Quan,et al. Salient type 1 interleukin 1 receptor expression in peripheral non-immune cells , 2018, Scientific Reports.
[10] P. Efthimiou,et al. Adult-Onset Still’s Disease , 2012, Drugs.
[11] A. Prost,et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. , 1995, Annals of the rheumatic diseases.
[12] M. Akizuki,et al. Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.
[13] J. Esdaile,et al. Adult Still's Disease: Manifestations, Disease Course, and Outcome in 62 Patients , 1991, Medicine.